{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:36:15Z","timestamp":1768440975826,"version":"3.49.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40120-025-00851-6","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T10:03:58Z","timestamp":1764756238000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancing Care in Myasthenia Gravis: What Can We Learn From the Multiple Sclerosis Community?"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-8617","authenticated-orcid":false,"suffix":"Jr.","given":"James F.","family":"Howard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Sadeghian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasa","family":"Savic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-1700","authenticated-orcid":false,"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"11","key":"851_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","volume":"10","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10(11):2235.","journal-title":"J Clin Med"},{"issue":"10","key":"851_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023\u201336.","journal-title":"Lancet Neurol"},{"issue":"3","key":"851_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"key":"851_CR4","unstructured":"Nowak RJ. Myasthenia gravis: challenges and burdens of disease. MDedge.com [online]. Available from: https:\/\/www.mdedge.com\/neurology\/article\/161081\/myasthenia-gravis-challenges-and-burdens-disease. Accessed 17 Oct 2025."},{"key":"851_CR5","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8206.1","volume":"5","author":"WD Phillips","year":"2016","unstructured":"Phillips WD, Vincent A. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Res. 2016;5:1513.","journal-title":"F1000Res"},{"issue":"1","key":"851_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.","journal-title":"Nat Rev Dis Primers"},{"key":"851_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00707","volume":"11","author":"LS Borges","year":"2020","unstructured":"Borges LS, Richman DP. Muscle-specific kinase myasthenia gravis. Front Immunol. 2020;11:707.","journal-title":"Front Immunol"},{"key":"851_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/ITT.S261414","volume":"9","author":"R Mantegazza","year":"2020","unstructured":"Mantegazza R, Vanoli F, Frangiamore R, Cavalcante P. Complement inhibition for the treatment of myasthenia gravis. Immunotargets Ther. 2020;9:317\u201331.","journal-title":"Immunotargets Ther"},{"issue":"4","key":"851_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis. Neurology. 2016;87(4):419\u201325.","journal-title":"Neurology"},{"issue":"4","key":"851_CR10","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s13760-024-02552-7","volume":"124","author":"JL De Bleecker","year":"2024","unstructured":"De Bleecker JL, Remiche G, Alonso-Jim\u00e9nez A, Van Parys V, Bissay V, Delstanche S, et al. Recommendations for the management of myasthenia gravis in Belgium. Acta Neurol Belg. 2024;124(4):1371\u201383.","journal-title":"Acta Neurol Belg"},{"issue":"5","key":"851_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16229","volume":"31","author":"NE Gilhus","year":"2024","unstructured":"Gilhus NE, Andersen H, Andersen LK, Boldingh M, Laakso S, Leopoldsdottir MO, et al. Generalized myasthenia gravis with acetylcholine receptor antibodies: a guidance for treatment. Eur J Neurol. 2024;31(5):e16229.","journal-title":"Eur J Neurol"},{"key":"851_CR12","doi-asserted-by":"publisher","first-page":"175628642312132","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A, Della Marina A, Hagenacker T, Hekmat K, et al. Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord. 2023;16:17562864231213240.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"851_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cen3.12739","volume":"14","author":"H Murai","year":"2023","unstructured":"Murai H, Utsugisawa K, Motomura M, Imai T, Uzawa A, Suzuki S. The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome. Clin Exp Neuroimmunol. 2023;14(1):19\u201327.","journal-title":"Clin Exp Neuroimmunol"},{"issue":"7","key":"851_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16280","volume":"31","author":"A Meisel","year":"2024","unstructured":"Meisel A, Sacc\u00e0 F, Spillane J, Vissing J. Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis. Eur J Neurol. 2024;31(7):e16280.","journal-title":"Eur J Neurol"},{"key":"851_CR15","unstructured":"Wiendl H, Meisel A, Marx A. Diagnostik und therapie myasthener syndrome. AWMF [online]. Available from: https:\/\/register.awmf.org\/assets\/guidelines\/030-087l_S2k_Diagnostik-Therapie-myasthener-Syndrome_2025-01.pdf. Accessed 17 Oct 2025."},{"key":"851_CR16","doi-asserted-by":"crossref","unstructured":"Cort\u00e9s-Vicente E, Hern\u00e1ndez R, Mart\u00ednez E, Pardo J, Rodr\u00edguez de Rivera FJ. Consensus recommendation for the treatment of generalised myasthenia gravis with anti-acetylcholine receptor antibodies (gMG AChR+) in Spain. Rare. 2025;3:100051.","DOI":"10.1016\/j.rare.2024.100051"},{"issue":"2","key":"851_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.59578\/jmsni.2024.15.2.59-71","volume":"15","author":"HS Lee","year":"2024","unstructured":"Lee HS, Chung HY, Kim SW, Sohn E, Nam TS, Shin KJ, et al. National consensus guidance for management of refractory myasthenia gravis. J Mult Scler Neuroimmunol. 2024;15(2):59\u201371.","journal-title":"J Mult Scler Neuroimmunol"},{"issue":"6","key":"851_CR18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/ncpneuro0810","volume":"4","author":"S Sathasivam","year":"2008","unstructured":"Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pract Neurol. 2008;4(6):317\u201327.","journal-title":"Nat Clin Pract Neurol"},{"issue":"4","key":"851_CR19","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/ene.14675","volume":"28","author":"C Tran","year":"2021","unstructured":"Tran C, Biswas A, Mendoza M, Katzberg H, Bril V, Barnett C. Performance of different criteria for refractory myasthenia gravis. Eur J Neurol. 2021;28(4):1375\u201384.","journal-title":"Eur J Neurol"},{"issue":"12","key":"851_CR20","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.nmd.2021.07.396","volume":"31","author":"NE Gilhus","year":"2021","unstructured":"Gilhus NE, Verschuuren JJGM, Hovland SIB, Simmonds H, Groot F, Palace J. Myasthenia gravis: do not forget the patient perspective. Neuromuscul Disord. 2021;31(12):1287\u201395.","journal-title":"Neuromuscul Disord"},{"key":"851_CR21","doi-asserted-by":"publisher","first-page":"175628561774913","DOI":"10.1177\/1756285617749134","volume":"11","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018;11:1756285617749134.","journal-title":"Ther Adv Neurol Disord"},{"issue":"02","key":"851_CR22","doi-asserted-by":"publisher","first-page":"E84","DOI":"10.1055\/s-0043-124983","volume":"2","author":"PP Urban","year":"2018","unstructured":"Urban PP, Jacobi C, Jander S. Treatment standards and individualized therapy of myasthenia gravis. Neurol Int Open. 2018;2(02):E84\u201392.","journal-title":"Neurol Int Open"},{"issue":"1","key":"851_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/0972-5229.148631","volume":"19","author":"R Kumar","year":"2015","unstructured":"Kumar R, Birinder SP, Gupta S, Singh G, Kaur A. Therapeutic plasma exchange in the treatment of myasthenia gravis. Indian J Crit Care Med. 2015;19(1):9\u201313.","journal-title":"Indian J Crit Care Med"},{"issue":"1","key":"851_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1941875210382918","volume":"1","author":"LC Wendell","year":"2011","unstructured":"Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011;1(1):16\u201322.","journal-title":"Neurohospitalist"},{"issue":"2","key":"851_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","volume":"36","author":"C Farmakidis","year":"2018","unstructured":"Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of myasthenia gravis. Neurol Clin. 2018;36(2):311\u201337.","journal-title":"Neurol Clin"},{"issue":"6","key":"851_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061597","volume":"11","author":"MK Alhaidar","year":"2022","unstructured":"Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current treatment of myasthenia gravis. J Clin Med. 2022;11(6):1597.","journal-title":"J Clin Med"},{"issue":"2","key":"851_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40259-024-00701-1","volume":"39","author":"L Gerischer","year":"2025","unstructured":"Gerischer L, Doksani P, Hoffmann S, Meisel A. New and emerging biological therapies for myasthenia gravis: a focussed review for clinical decision-making. BioDrugs. 2025;39(2):185\u2013213.","journal-title":"BioDrugs"},{"key":"851_CR28","unstructured":"Alexion\/AstraZeneca Rare Disease. ULTOMIRIS\u00ae\u00a0approved in Japan for the treatment of adults with generalised myasthenia gravis. [online]. [Accessed 17 October 2025] Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/ultomiris-approved-in-japan-for-the-treatment-of-adults-with-generalised-myasthenia-gravis.html"},{"key":"851_CR29","unstructured":"Alexion\/AstraZeneca Rare Disease. ULTOMIRIS\u00ae\u00a0EU SmPC [online]. [Accessed 17 October 2025] Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ultomiris-epar-product-information_en.pdf"},{"key":"851_CR30","unstructured":"Alexion\/AstraZeneca Rare Disease. ULTOMIRIS\u00ae\u00a0US PI [online]. [Accessed 17 October 2025] Available from: https:\/\/alexion.com\/documents\/ultomiris_uspi"},{"key":"851_CR31","unstructured":"Argenx BV. VYVGART\u00ae\u00a0EU SmPC [online]. [Accessed 17 October 2025] Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vyvgart-epar-product-information_en.pdf"},{"key":"851_CR32","unstructured":"Argenx BV. VYVGART\u00ae\u00a0US PI [online]. [Accessed 17 October 2025] Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761304s000lbl.pdf"},{"key":"851_CR33","unstructured":"UCB. ZILBRYSQ\u00ae\u00a0EU SmPC [online]. [Accessed 17 October 2025] Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zilbrysq-epar-product-information_en.pdf"},{"key":"851_CR34","unstructured":"UCB. ZILBRYSQ\u00ae\u00a0Japan PI [online]. [Accessed 17 October 2025] Available from: https:\/\/www.pmda.go.jp\/drugs\/2023\/P20231018001\/820110000_30500AMX00251_B100_1.pdf"},{"key":"851_CR35","unstructured":"UCB. ZILBRYSQ\u00ae\u00a0US PI [online]. [Accessed 17 October 2025] Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216834s000lbl.pdf"},{"key":"851_CR36","unstructured":"UCB. RYSTIGGO\u00ae EU SmPC [online]. [Accessed 17 October 2025] Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rystiggo-epar-product-information_en.pdf"},{"key":"851_CR37","unstructured":"UCB. RYSTIGGO\u00ae US PI [online]. [Accessed 17 October 2025] Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761286s000lbl.pdf"},{"key":"851_CR38","unstructured":"UCB. RYSTIGGO\u00ae\u00a0Japan PI [online]. [Accessed 17 October 2025] Available from: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/820110_6399432A1028_1_05"},{"key":"851_CR39","unstructured":"Alexion\/AstraZeneca Rare Disease. SOLIRIS\u00ae\u00a0approved in Japan for paediatric patients with generalised myasthenia gravis (gMG). [online]. [Accessed 17 October 2025] Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/soliris-approved-japan-paediatric-patients-generalised-myasthenia-gravis-gmg.html"},{"key":"851_CR40","unstructured":"Alexion\/AstraZeneca Rare Disease. SOLIRIS\u00ae\u00a0EU SmPC [online]. [Accessed 17 October 2025] Available from: https:\/\/www.medicines.org.uk\/emc\/product\/362\/smpc"},{"key":"851_CR41","unstructured":"Alexion\/AstraZeneca Rare Disease. SOLIRIS\u00ae\u00a0US PI [online]. [Accessed 17 October 2025] Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125166s422lbl.pdf"},{"key":"851_CR42","doi-asserted-by":"publisher","first-page":"116419","DOI":"10.1016\/j.jns.2019.08.004","volume":"407","author":"H Murai","year":"2019","unstructured":"Murai H, Uzawa A, Suzuki Y, Imai T, Shiraishi H, Suzuki H, Okumura M, O'Brien F, Wang JJ, Fujita KP, Utsugisawa K, REGAIN Study Group. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: a subgroup analysis of the REGAIN open-label extension study. J Neurol Sci. 2019;407:116419.","journal-title":"J Neurol Sci"},{"key":"851_CR43","unstructured":"Janssen Biotech, Inc. IMAAVY\u2122 US PI [online]. [Accessed 17 October 2025] Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761430s000lbl.pdf"},{"key":"851_CR44","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3389\/fneur.2020.00538","volume":"11","author":"D Menon","year":"2020","unstructured":"Menon D, Barnett C, Bril V. Novel treatments in myasthenia gravis. Front Neurol. 2020;11:538.","journal-title":"Front Neurol"},{"issue":"5","key":"851_CR45","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive Phase 3 study. Lancet Neurol. 2023;22(5):383\u201394.","journal-title":"Lancet Neurol"},{"issue":"5","key":"851_CR46","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard Jr","year":"2023","unstructured":"Howard JF Jr, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, Phase 3 study. Lancet Neurol. 2023;22(5):395\u2013406.","journal-title":"Lancet Neurol"},{"issue":"1","key":"851_CR47","doi-asserted-by":"publisher","DOI":"10.4110\/in.2022.22.e9","volume":"22","author":"SM Jung","year":"2022","unstructured":"Jung SM, Kim WU. Targeted immunotherapy for autoimmune disease. Immune Netw. 2022;22(1):e9.","journal-title":"Immune Netw"},{"issue":"3","key":"851_CR48","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00415-025-12922-7","volume":"272","author":"SNM Binks","year":"2025","unstructured":"Binks SNM, Morse IM, Ashraghi M, Vincent A, Waters P, Leite MI. Myasthenia gravis in 2025: five new things and four hopes for the future. J Neurol. 2025;272(3):226.","journal-title":"J Neurol"},{"issue":"12","key":"851_CR49","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1111\/ene.15872","volume":"30","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Pane C, Espinosa PE, Sormani MP, Signori A. Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. Eur J Neurol. 2023;30(12):3854\u201367.","journal-title":"Eur J Neurol"},{"issue":"1","key":"851_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","volume":"26","author":"R Dobson","year":"2019","unstructured":"Dobson R, Giovannoni G. Multiple sclerosis \u2013 a review. Eur J Neurol. 2019;26(1):27\u201340.","journal-title":"Eur J Neurol"},{"key":"851_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596981","volume":"11","author":"K Lazaridis","year":"2020","unstructured":"Lazaridis K, Tzartos SJ. Myasthenia gravis: autoantibody specificities and their role in MG management. Front Neurol. 2020;11:596981.","journal-title":"Front Neurol"},{"key":"851_CR52","unstructured":"Stewart J. What are the new drugs used for multiple sclerosis (MS)? Drugs.com. [online]. [Accessed 17 October 2025] Available from: https:\/\/www.drugs.com\/medical-answers\/new-drugs-treatment-multiple-sclerosis-ms-3510640\/"},{"issue":"12","key":"851_CR53","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","volume":"36","author":"L Freeman","year":"2022","unstructured":"Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T. High-efficacy therapies for treatment-na\u00efve individuals with relapsing-remitting multiple sclerosis. CNS Drugs. 2022;36(12):1285\u201399.","journal-title":"CNS Drugs"},{"issue":"Suppl 1","key":"851_CR54","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","volume":"9","author":"G Giovannoni","year":"2016","unstructured":"Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9(Suppl 1):S5\u201348.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"851_CR55","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1212\/CPJ.0000000000001045","volume":"11","author":"TL Vollmer","year":"2021","unstructured":"Vollmer TL, Nair KV, Williams IM, Alvarez E. Multiple sclerosis phenotypes as a continuum: the role of neurologic reserve. Neurol Clin Pract. 2021;11(4):342\u201351.","journal-title":"Neurol Clin Pract"},{"issue":"6","key":"851_CR56","doi-asserted-by":"publisher","first-page":"E311","DOI":"10.1016\/S2665-9913(20)30103-X","volume":"2","author":"P Emery","year":"2020","unstructured":"Emery P, Duquenne L. It\u2019s never too soon to treat rheumatoid arthritis: finally, some supportive evidence. Lancet Rheumatol. 2020;2(6):E311\u20133.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"851_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010048","volume":"13","author":"JT Molina","year":"2023","unstructured":"Molina JT, Hern\u00e1ndez-Cruz B, Corominas H. Initial treatment with biological therapy in rheumatoid arthritis. J Clin Med. 2023;13(1):48.","journal-title":"J Clin Med"},{"issue":"6","key":"851_CR58","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","volume":"120","author":"GR Lichtenstein","year":"2025","unstructured":"Lichtenstein GR, Loftus EV, Afzali A, Long MD, Barnes EL, Isaacs KL, et al. ACG clinical guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2025;120(6):1225\u201364.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"851_CR59","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/WCO.0000000000000319","volume":"29","author":"PP Axisa","year":"2016","unstructured":"Axisa PP, Hafler DA. Multiple sclerosis: genetics, biomarkers, treatments. Curr Opin Neurol. 2016;29(3):345\u201353.","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"851_CR60","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/14737175.2023.2207739","volume":"23","author":"A Evoli","year":"2023","unstructured":"Evoli A, Damato V. Conventional and emerging treatments and controversies in myasthenia gravis. Expert Rev Neurother. 2023;23(5):445\u201356.","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"851_CR61","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000241","volume":"2","author":"M DeHart-McCoyle","year":"2023","unstructured":"DeHart-McCoyle M, Patel S, Du X. New and emerging treatments for myasthenia gravis. BMJ Med. 2023;2(1):e000241.","journal-title":"BMJ Med"},{"issue":"5","key":"851_CR62","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/13543784.2021.1897567","volume":"30","author":"JF Howard Jr.","year":"2021","unstructured":"Howard JF Jr., Vissing J, Gilhus NE, Leite MI, Utsugisawa K, Duda PW, et al. Zilucoplan: an investigational complement C5 inhibitor for the treatment of acetylcholine receptor autoantibody-positive generalized myasthenia gravis. Expert Opin Investig Drugs. 2021;30(5):483\u201393.","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"851_CR63","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00415-025-13113-0","volume":"272","author":"C Hewamadduma","year":"2025","unstructured":"Hewamadduma C, Freimer M, Genge A, Leite MI, Utsugisawa K, Vu T, et al. Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis. J Neurol. 2025;272(7):457.","journal-title":"J Neurol"},{"issue":"4","key":"851_CR64","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000506310","volume":"54","author":"E Guastafierro","year":"2020","unstructured":"Guastafierro E, Tramacere I, Toppo C, Leonardi M, Mantegazza R, Bonanno S, et al. Employment in myasthenia gravis: a systematic literature review and meta-analysis. Neuroepidemiology. 2020;54(4):304\u201312.","journal-title":"Neuroepidemiology"},{"issue":"2","key":"851_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013278","volume":"7","author":"Y Nagane","year":"2017","unstructured":"Nagane Y, Murai H, Imai T, Yamamoto D, Tsuda E, Minami N, et al. Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study. BMJ Open. 2017;7(2):e013278.","journal-title":"BMJ Open"},{"issue":"1","key":"851_CR66","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12883-016-0757-2","volume":"16","author":"A Frost","year":"2016","unstructured":"Frost A, Svendsen ML, Rahbek J, Stapelfeldt CM, Nielsen CV, Lund T. Labour market participation and sick leave among patients diagnosed with myasthenia gravis in Denmark 1997\u20132011: a Danish nationwide cohort study. BMC Neurol. 2016;16(1):224.","journal-title":"BMC Neurol"},{"issue":"7","key":"851_CR67","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jocn.2015.01.022","volume":"22","author":"S Blum","year":"2015","unstructured":"Blum S, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P. Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci. 2015;22(7):1164\u20139.","journal-title":"J Clin Neurosci"},{"key":"851_CR68","unstructured":"MS International Federation. Global MS employment report 2016. [online]. [Accessed 17 October 2025] Available from: https:\/\/www.msif.org\/wp-content\/uploads\/2016\/05\/Global-MS-Employment-Report-2016.pdf"},{"issue":"11","key":"851_CR69","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A, Feresiadou A, Hansson W, Hietala MA, et al. Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol. 2022;79(11):1105\u201312.","journal-title":"JAMA Neurol"},{"issue":"6","key":"851_CR70","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jnnp-2022-330519","volume":"94","author":"A Uzawa","year":"2023","unstructured":"Uzawa A, Suzuki S, Kuwabara S, Akamine H, Onishi Y, Yasuda M, et al. Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry. 2023;94(6):467\u201373.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"851_CR71","doi-asserted-by":"publisher","first-page":"1259484","DOI":"10.3389\/fneur.2023.1259484","volume":"14","author":"L Zhen","year":"2023","unstructured":"Zhen L, Zhao X, Li W, Wu J, Shang H, Chen S, et al. Effectiveness of early glucocorticoids in myasthenia gravis: a retrospective cohort study. Front Neurol. 2023;14:1259484.","journal-title":"Front Neurol"},{"key":"851_CR72","unstructured":"Rebecca Ayers. Nerve surgery and nerve repair. [online]. [Accessed 17 October 2025] Available from: https:\/\/www.rebeccaayers.co.nz\/procedures-and-information\/hand-surgery\/nerve-surgery-and-nerve-repair\/nerve-surgery-and-nerve-repair"},{"key":"851_CR73","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/698256","volume":"2014","author":"D Grinsell","year":"2014","unstructured":"Grinsell D, Keating CP. Peripheral nerve reconstruction after injury: a review of clinical and experimental therapies. BioMed Res Int. 2014;2014:698256.","journal-title":"BioMed Res Int"},{"issue":"5","key":"851_CR74","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/mus.26654","volume":"60","author":"B Vannucci","year":"2019","unstructured":"Vannucci B, Santosa KB, Keane AM, Jablonka-Shariff A, Lu CY, Yan Y, et al. What is normal? Neuromuscular junction reinnervation after nerve injury. Muscle Nerve. 2019;60(5):604\u201312.","journal-title":"Muscle Nerve"},{"issue":"4","key":"851_CR75","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","volume":"97","author":"C Baecher-Allan","year":"2018","unstructured":"Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple sclerosis: mechanisms and immunotherapy. Neuron. 2018;97(4):742\u201368.","journal-title":"Neuron"},{"issue":"3","key":"851_CR76","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40263-017-0412-5","volume":"31","author":"CE van Munster","year":"2017","unstructured":"van Munster CE, Uitdehaag BM. Outcome measures in clinical trials for multiple sclerosis. CNS Drugs. 2017;31(3):217\u201336.","journal-title":"CNS Drugs"},{"issue":"5","key":"851_CR77","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/pn-2025-004655","volume":"25","author":"S Jacob","year":"2025","unstructured":"Jacob S, Farrugia ME, Hewamadduma C, Norwood F, Hill M, Leite MI, et al. Association of British neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update). Pract Neurol. 2025;25(5):422\u201337.","journal-title":"Pract Neurol"},{"issue":"3","key":"851_CR78","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1007\/s00415-021-10674-8","volume":"269","author":"G Pardo","year":"2022","unstructured":"Pardo G, Coates S, Okuda DT. Outcome measures assisting treatment optimization in multiple sclerosis. J Neurol. 2022;269(3):1282\u201397.","journal-title":"J Neurol"},{"issue":"Pt 5","key":"851_CR79","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/brain\/122.5.871","volume":"122","author":"GR Cutter","year":"1999","unstructured":"Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122(Pt 5):871\u201382.","journal-title":"Brain"},{"issue":"1","key":"851_CR80","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/1352458516638941","volume":"23","author":"D Cadavid","year":"2017","unstructured":"Cadavid D, Cohen JA, Freedman MS, Goldman MD, Hartung HP, Havrdova E, et al. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler. 2017;23(1):94\u2013105.","journal-title":"Mult Scler"},{"issue":"2","key":"851_CR81","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","volume":"21","author":"JJGM Verschuuren","year":"2022","unstructured":"Verschuuren JJGM, Palace J, Murai H, Tannemaat MR, Kaminski HJ, Bril V. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):189\u2013202.","journal-title":"Lancet Neurol"},{"issue":"2","key":"851_CR82","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","volume":"21","author":"A Punga","year":"2022","unstructured":"Punga A, Maddison P, Heckmann J, Guptill J, Evoli A. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):176\u201388.","journal-title":"Lancet Neurol"},{"issue":"6","key":"851_CR83","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16180","volume":"31","author":"F Sacc\u00e0","year":"2024","unstructured":"Sacc\u00e0 F, Salort-Campana E, Jacob S, Cort\u00e9s-Vicente E, Schneider-Gold C. Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy. Eur J Neurol. 2024;31(6):e16180.","journal-title":"Eur J Neurol"},{"issue":"5","key":"851_CR84","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1053\/j.gastro.2022.01.024","volume":"162","author":"N Plevris","year":"2022","unstructured":"Plevris N, Lees CW. Disease monitoring in inflammatory bowel disease: evolving principles and possibilities. Gastroenterology. 2022;162(5):1456-75.e1.","journal-title":"Gastroenterology"},{"key":"851_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100111","volume":"4","author":"F Stascheit","year":"2021","unstructured":"Stascheit F, Hotter B, Hoffmann S, Kohler S, Lehnerer S, Sputtek A, et al. Calprotectin as potential novel biomarker in myasthenia gravis. J Transl Autoimmun. 2021;4:100111.","journal-title":"J Transl Autoimmun"},{"issue":"3","key":"851_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.neumar.2025.100094","volume":"2","author":"AM De Le\u00f3n","year":"2025","unstructured":"De Le\u00f3n AM. Biomarkers in autoimmune myasthenia gravis: a narrative review. NeuroMarkers. 2025;2(3):100094.","journal-title":"NeuroMarkers"},{"issue":"1","key":"851_CR87","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10571-025-01585-7","volume":"45","author":"P Paudel","year":"2025","unstructured":"Paudel P, Sah A. MicroRNAs as diagnostic biomarkers of myasthenia gravis: a systematic review and meta-analysis. Cell Mol Neurobiol. 2025;45(1):71.","journal-title":"Cell Mol Neurobiol"},{"issue":"13","key":"851_CR88","doi-asserted-by":"publisher","DOI":"10.1172\/JCI180012","volume":"134","author":"A Bodansky","year":"2024","unstructured":"Bodansky A, Yu DJ, Rallistan A, Kalaycioglu M, Boonyaratanakornkit J, Green DJ, et al. Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR T cell therapies in autoimmunity. J Clin Invest. 2024;134(13):e180012.","journal-title":"J Clin Invest"},{"key":"851_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596382","volume":"11","author":"JLS Thomsen","year":"2020","unstructured":"Thomsen JLS, Andersen H. Outcome measures in clinical trials of patients with myasthenia gravis. Front Neurol. 2020;11:596382.","journal-title":"Front Neurol"},{"issue":"1","key":"851_CR90","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/mus.28417","volume":"72","author":"K Ruzhansky","year":"2025","unstructured":"Ruzhansky K, Li Y, Wolfe GI, Muppidi S, Guptill JT, Hehir MK, et al. Standardization of myasthenia gravis outcome measures in clinical practice: a report of the MGFA task force. Muscle Nerve. 2025;72(1):56\u201365.","journal-title":"Muscle Nerve"},{"key":"851_CR91","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jocn.2021.07.020","volume":"91","author":"Y Luo","year":"2021","unstructured":"Luo Y, Dong X, Peng Y, Cui B, Yan C, Jin W, et al. Evaluation of outcome measures for myasthenia gravis subgroups. J Clin Neurosci. 2021;91:270\u20135.","journal-title":"J Clin Neurosci"},{"issue":"1","key":"851_CR92","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s13023-021-02064-0","volume":"16","author":"S Cleanthous","year":"2021","unstructured":"Cleanthous S, Mork AC, Regnault A, Cano S, Kaminski HJ, Morel T. Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease. Orphanet J Rare Dis. 2021;16(1):457.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"851_CR93","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s40120-023-00464-x","volume":"12","author":"A Regnault","year":"2023","unstructured":"Regnault A, Morel T, de la Loge C, Mazerolle F, Kaminski HJ, Habib AA. Measuring overall severity of myasthenia gravis (MG): evidence for the added value of the MG Symptoms PRO. Neurol Ther. 2023;12(5):1573\u201390.","journal-title":"Neurol Ther"},{"key":"851_CR94","doi-asserted-by":"publisher","first-page":"1368525","DOI":"10.3389\/fneur.2024.1368525","volume":"15","author":"A Regnault","year":"2024","unstructured":"Regnault A, Habib AA, Creel K, Kaminski HJ, Morel T. Clinical meaningfulness and psychometric robustness of the MG Symptoms PRO scales in clinical trials in adults with myasthenia gravis. Front Neurol. 2024;15:1368525.","journal-title":"Front Neurol"},{"issue":"2","key":"851_CR95","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/mus.26069","volume":"58","author":"C Tran","year":"2018","unstructured":"Tran C, Bril V, Katzberg HD, Barnett C. Fatigue is a relevant outcome in patients with myasthenia gravis. Muscle Nerve. 2018;58(2):197\u2013203.","journal-title":"Muscle Nerve"},{"key":"851_CR96","unstructured":"HealthMeasures. PROMIS\u00ae (Patient-Reported Outcomes Measurement Information System) [online]. [Accessed 17 October 2025] Available from: https:\/\/www.healthmeasures.net\/explore-measurement-systems\/promis"},{"issue":"3","key":"851_CR97","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/WCO.0000000000000561","volume":"31","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G. Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm. Curr Opin Neurol. 2018;31(3):233\u201343.","journal-title":"Curr Opin Neurol"},{"issue":"10","key":"851_CR98","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S1474-4422(06)70577-4","volume":"5","author":"G Giovannoni","year":"2006","unstructured":"Giovannoni G, Cutter GR, Lunemann J, Martin R, M\u00fcnz C, Sriram S, et al. Infectious causes of multiple sclerosis. Lancet Neurol. 2006;5(10):887\u201394.","journal-title":"Lancet Neurol"},{"issue":"4","key":"851_CR99","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/14656566.2024.2332610","volume":"25","author":"SP Uysal","year":"2024","unstructured":"Uysal SP, Morren JA. Promising therapies for the treatment of myasthenia gravis. Expert Opin Pharmacother. 2024;25(4):395\u2013408.","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"851_CR100","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon D, Bril V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs. 2022;82(8):865\u201387.","journal-title":"Drugs"},{"key":"851_CR101","unstructured":"Myasthenia Gravis Foundation of America. 15th MGFA International Conference on Myasthenia and Related Disorders. [online]. [Accessed 17 October 2025] Available from: https:\/\/myasthenia.org\/events\/2025-international-conference\/"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00851-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00851-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00851-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:06:03Z","timestamp":1768403163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00851-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["851"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00851-6","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"James F. Howard, Jr. has received research support (paid to his institution) from Ad Scientiam, Alexion\/AstraZeneca Rare Disease, argenx, Cartesian Therapeutics, the Centers for Disease Control and Prevention, Merck EMD Serono,\u00a0the Muscular Dystrophy Association, the Myasthenia Gravis Foundation of America, the National Institutes of Health, NMD Pharma and UCB; has received honoraria\/consulting fees from AcademicCME, Alexion\/AstraZeneca Rare Disease, Amgen, argenx, Biohaven Ltd, Cartesian Therapeutics, CheckRare CME, CorEvitas, Curie.Bio, Hansa Biopharma, Lundbeck, Medscape CME,\u00a0Merck EMD Serono, Novartis, PeerView CME, Physicians\u2019 Education Resource (PER) CME, PlatformQ CME, Regeneron Pharmaceuticals, Sanofi US, TG Therapeutics, Toleranzia AB and UCB; and has received non-financial support from Alexion\/AstraZeneca Rare Disease, argenx, Biohaven Ltd, Cartesian Therapeutics, Toleranzia AB and UCB. In the last 2\u00a0years, Professor Gavin Giovannoni has received compensation for serving as a Consultant or speaker, or research support, from Astoria Biologica, Aurinia Pharmaceuticals, Biogen, BioNTech, BMS-Celgene, GlaxoSmithKline, Janssen\/J&J, Japanese Tobacco, Kiniksa, Merck KGaA\/EMD Serono, Moderna, Novartis, Roche\/Genentech, Sandoz, Sanofi, UCB, Vir Biotechnology, Viracta and Zenas BioPharma. Mona Sadeghian was an employee and shareholder of UCB at the time of the conception and initial development of this publication. Natasa Savic is an employee and shareholder of UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"We confirm that we have read the journal\u2019s position on issues involved in ethical publication and affirm that this commentary is consistent with those guidelines. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}